ProCE Banner Activity

CE / CME

APPlexus Oncology Spring: Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Video

In this certified on-demand webcast, experts review emerging data on antibody–drug conjugates currently used to treat breast cancer and discuss how to navigate potential challenges associated with their use, including treatment sequencing and adverse events.

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: April 10, 2025

Expiration: October 09, 2025

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE).

ProCE Banner

Supporters

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with breast cancer. 

Program Learning Goal

This activity aims to improve learners’ knowledge and competence in safely and effectively incorporating antibody–drug conjugates into personalized care of patients with breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate patients’ treatment goals, preferences, and quality of life considerations into decisions related to ADC therapy selection and supportive care

  • Recommend treatment options incorporating ADCs to appropriate patients with breast cancer based on the latest evidence, approvals, and guidelines

  • Educate patients and colleagues on the latest ADC safety data and how an ADC’s safety profile is related to its structural, mechanistic, and other unique characteristics

  • Plan evidence-based strategies for monitoring and managing AEs related to ADC therapy using the latest evidence, guidelines, and expert recommendations

Disclosure

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Elizabeth Diaz, PA-C, has no relevant financial relationships to disclose.

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Kimberly Podsada, MSN, NP-C, CNS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Novartis, Pfizer.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Jazz, Lilly, Merck, Pfizer, Takeda.

Nicolle Rochino, PharmD, RPh: employee (relationship has ended): Novo Nordisk.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 10, 2025, through October 09, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 09, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.